All Episodes
The Uromigos — 486 episodes · page 1 of 5
Episode 520: ESMO 2026 Preview
Episode 519: What is the Appropriate Approach to Adjuvant Therapy for UTUC?
Episode 518: PSMAddition in Clinical Practice
Episode 517: Casdatifan Clinical Data in RCC and Translational Correlates
Episode 516: The Influence of Hypoxia on Response and Resistance in RCC
Episode 515: PROTEUS - A Reflection on the Data and Controversies with Neha Vapiwala
Episode 514: Artificial Intelligence in Cancer Drug Development
Episode 513: Trials and Tribulations of Investigator-initiated Research
Episode 512: ENZA-P Nature Medicine translational data
Episode 510: ADCs in Prostate Cancer
Episode 509: ASCO 2026 Review
Episode 508: ASCO 2026 Plenary - PROTEUS: ADT +/- Apalutamide in high-risk Localized Prostate Cancer
Episode 507: ASCO 2026 - TALAPRO-3
Episode 506: ASCO 2026 - How do we measure quality of life in GU patients?
Episode 505 : ASCO 2026 - RAMPART
Episode 504: ASCO 2026 - ADC Drug Development in Urothelial Cancer
Episode 499: APCCC 2026 - Radioligands in Prostate Cancer
Episode 503: ASCO 2026 Preview
Episode 502: AUA 2026 and FDA bladder cancer meeting
Episode 501: APCCC 2026 - Biochemically-relapsed Prostate cancer
Episode 500: RAS Inhibition in Pancreatic Cancer (yes this is the Uromigos podcast..)
Episode 499: APCCC 2026 - Radioligands
Episode 498: APCCC 2026 - mCRPC
Episode 497: Reflections on the capivasertib ODAC
Episode 496: APCCC 2026 - mHSPC Landscape
Episode 495: APCCC 2026 - Locally-advanced Prostate Cancer
Episode 494: Duration of EVP in Multiple Urothelial Cancer Settings / Paper of the Month PPARG Inverse Agonist
Episode 493: The Role of Chemotherapy in mHSPC
Episode 492: Novel Biomarkers and Targets in Germ Cell Tumors
Episode 491 Uromigos Japan: ASCO GU26速報！前立腺がん&腎がん
Episode 490: Systemic Therapy Only in Patients wtih MIBC
Episode 489: Live Podcast From EAU
Episode 488: Uromigos Japan - ASCO GU26速報！尿路上皮がん
Episodio 485: ASCO GU 2026 - LITESPARK 011: Len/Belzutifan vs Cabo
Episodio 484: ASCO GU 2026 - LITESPARK 022: Pembro adyuvante + Belzutifan en cáncer renal
Episodio 483: ASCO GU 2026 - KEYNOTE B15: EVP neoadyuvante vs Gem/Cis en cáncer de vejiga músculo-invasivo cisplatino elegible
Episodio 482: ASCO GU 2026 - SUNRISE 2
Episodio 480: ASCO GU 2026 - Resultados finales de SG de PEACE-3 y BRCAway
Episode 487: ASCO GU 2026 recap
Episode 486: ctDNA and utDNA Data in Peri-operative Urothelial cancer
Episode 485: ASCO GU 2026 - LITESPARK 011: Len/Belzu vs Cabo
Episode 484: ASCO GU 2026 - LITESPARK 022: Adjuvant Pembro + Belzutifan in RCC
Episode 482: ASCO GU 2026 - SUNRISE 2
Episode 483: ASCO GU 2026 - KEYNOTE B15: Neoadjuvant EVP vs Gem/Cis in Cis-eligible MIBC
Episode 480: ASCO GU 2026 - PEACE-3 and BRCAway Final OS Results
Episode 479: Does the Timing of IO Infusion Impact Clinical Outcomes? A Critical Analysis
Episode 478: Prostate Cancer Working Group 4 (PCWG 4) criteria
Episode 477: Uromigos Japan - GU Oncology 2025を総括!
Episode 476: ASCO GU 2026 Preview
Episode 475: Depth of Response and Overall Survival for IO-based Regimens in mRCC: Results of an FDA Analysis
Episode 474: Uromigos Shorts - IO-refractory Urothelial Cancer
Episode 473: Uromigos Shorts - EMBARK and BCR Prostate Cancer
Episode 472: Uromigos Shorts - Variant Histology Bladder Cancer
Episode 471: Uromigos Shorts - ADCs and BiTEs in Prostate Cancer
Episode 470: Bladder Cancer Year in Review
Episode 469: Prostate Cancer year in Review
Episode 468: RCC Year in Review
Episode 442: The History of ARPI Development in Prostate Cancer
Episode 466: #UromigosLive 2025 - Novel Therapy in mRCC
Episode 465: #UromigosLive 2025 - Adjuvant Therapy in RCC
Episode 464: #UromigosLive 2025 - The Evolving Landscape of mHSPC
Episode 459: #UromigosLive 2025 - Radioligands in Prostate Cancer
Episode 458: #UromigosLive 2025 - Mock ODAC
Episode 463: #UromigosLive 2025 Tres Uramigas: Resumen de la sesión sobre cáncer de vejiga metastásico
Episode 462 #UromigosLive 2025: Tres Uramigas - Resumen de la sesión sobre cáncer de vejiga músculo-invasivo
Episode 461: #UromigosLive 2025 -Uromigos Japan - ウロミーゴズライブ2025: 筋層浸潤膀胱がんセッションの振り返り
Episode 460 #UromigosLive 2025: Uromigos Japan - ウロミーゴズライブ2025: 転移性膀胱がんセッションの振り返り
Episode 457: #UromigosLive 2025: ADCs in Bladder Cancer
Episode 456: #UromigosLive 2025: Peri-operative Therapy for Urothlial Cancer
Episode 455: ESMO 2025 Urothelial Cancer Review
Episode 454: ESMO 2025 Prostate and Kidney Cancer Review
Episode 453: ESMO 2025 - IMvigor011
Episode 452: ESMO 2025 - DV+ toripalimab in bladder cancer
Episode 451: ESMO 2025 - PSMAddition
Episode 450: ESMO 2025 - CAPITELLO
Episode 449: ESMO 2025 - ENZARAD
Episode 448: Neoadjuvant EV/Pembro in Cis-ineligible MIBC
Episode 447: ESMO 2025 - RAMPART
Episode 446: ESMO 2025 - OPTIC and front-line RCC triplets
Episode 445: ESMO 2025 - Systemic Checkpoint Inhibition plus BCG in NMIBC (POTOMAC and ALBAN)
Episode 444: ESMO 2025 Preview - Prostate and Renal Cancer
Episode 443: ESMO 2025 Bladder Cancer Preview
Episode 441: The History of IO in Urothelial Cancer - Part 2
Episode 440: The History of IO in Urothelial Cancer - Part 1
Episode 439: Transcriptome Expression and Treatment Sensitivity in Prostate Cancer
Episode 438: The History of Testis Cancer Treatment
Episode 437: Uromigos Japan - バルバーサ (Erdafitinib)を実臨床でどう使うか！
Episode 436: The History of IO in RCC - Part 2
Episode 435: The History of IO in RCC - Part 1
Episode 434: IMPACT series - A Walk Through the History of VEGF TKI Development in RCC
Episode 433: Uromigos Japan - 改訂版ASCO mCRPCガイドライン
Episode 432: ASCO 2025 Rapid Oral Session RCC/Bladder Recap
Episode 431: IMPACT series - Axel Bex on Impactful RCC Clinical Trials
Episode 430: Structured Exercise Improves DFS/OS after Adjuvant Therapy in Colorectal Cancer - Does This Apply to GU Cancers?
Episode 429: ASCO2025レポート
Episode 428: ASCO 2025 Recap
Episode 427: Emerging Data in Non-muscle Invasive Bladder Cancer (NMIBC)
Episode 426 - ASCO 2025: AMPLITUDE Phase 3 of PARPi in mHSPC
Episode 425: ASCO 2025 - AI-enabled selection of patients for benefit of ADT + ARPI
Episode 424: ASCO 2025 - Emergency podcast on the prostate rapid oral session